PHEN,Inc. © 2017 All rights reserved
EMBARK Patient Summary
PHEN Clinical Trials Rally
The EMBARK clinical trial is to assess the safety and effectiveness of a combination of the FDA approved drugs Enzalutamide (Xtandi) plus Leuprolide (Lupron) in patients with prostate cancer progressing (but not spread to other parts of the body) after being treated with surgery or radiation or both.
Patients who participate in the EMBARK trial are randomly (by chance) assigned to either a group to receive Enzalutamide plus Leuprolide or to a group which will receive only Leuprolide which is the standard of care for patients with high-risk non-metastatic prostate cancer.
EMBARK is a phase 3 clinical trial which will enroll 1860 patients. The trial began in 2014 and the primary completion date is 2020.
Possible patient benefits include increasing the time before prostate cancer spreads (progresses) and metastasizes, and prolonging life. Another benefit is that all patients participating will receive the standard of care treatment Leuprolide (Lupron).
If you are interested in this trial you can take these actions:
PHEN Contact: 617-481-4020 x3
EMBARK Sponsor: Pfizer (formerly Medivation)